All In Biotech

Drug Trial Radar · NCT05040126

Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India

Evaluate the Effectiveness, Safety and Tolerability of Various Doses of Linezolid in Combination With Bedaquiline and Pretomanid in Adults With Pre-Extensively Drug-Resistant (Pre-XDR), Or Treatment Intolerant/Non-responsive Multidrug-Resistant (MDRTI/NR) Pulmonary Tuberculosis in India

Last checked: Nov 19, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

400

Planned (sponsor's estimate)

Start

Oct 7, 2021

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Tuberculosis Research Centre, IndiaGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
International Union Against Tuberculosis and Lung Diseases; Sarvodaya Charitable Trust Hospital, Ghatkopar, Mumbai; Shatabdi Centenary Hospital, Govandi, Mumbai; King George's Medical College and Hospital, Lucknow; SN Medical College, Agra; Govt Medical College & Hospital, Bhavnagar; Govt. Medical College & Hospital, Surat; National Institute of Tuberculosis and Respiratory Diseases, New Delhi; Rajan Babu Institute of Pulmonary Medicine and Tuberculosis, Delhi; Govt.Rajaji Medical college and hospital, Madurai
First posted
Sep 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Existing problem with DR TB management: Injectable regimens for longer duration with toxicity Poor adherence, treatment failures, continued transmission Need of the study: Oral regimens of shorter duration Improved treatment adherence Implementation of community-based models of care Reduction in direct costs and indirect costs of patients Improved treatment outcomes Need for shorter, tolerable and effective regimen Hence modified BPaL regimen is designed to study the newer shorter oral in varying doses of Linezolid for pre XDR Tb patients and MDR TI/NR patients

Conditions

  • Pre-Extensively Drug-Resistant Pulmonary TB
  • Treatment Intolerant Multidrug-Resistant Pulmonary TB
  • Non-responsive Multidrug-Resistant Pulmonary TB

Interventions

  • LinezolidDrug

    Participants will have a screening period of up to 14 days and will be randomized to one of the study arms in the ratio of 1:1:1, using an interactive web response system. Each participant will receive 26 weeks of treatment. If the participant's 16th-week sample remains culture positive, treatment will be extended up to 39 weeks. Participants will be followed for 48 weeks after the end of treatment

  • BedaquilineDrug

    Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks in all three arms

  • PretomanidDrug

    Pretomanid is administered as one tablet once a day for 26 weeks in all three arms

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sustained Treatment successTime frame: 12 months after successful TB treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • S N Medical College

    Agra, Uttar Pradesh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.